Literature DB >> 24715835

Breast care.

.   

Abstract

Year:  2012        PMID： 24715835      PMCID： PMC3971802          DOI： 10.1159/000345902

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  19 in total

1.  Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis.

Authors:  Kathryn P Lowry; Janie M Lee; Chung Y Kong; Pamela M McMahon; Michael E Gilmore; Jessica E Cott Chubiz; Etta D Pisano; Constantine Gatsonis; Paula D Ryan; Elissa M Ozanne; G Scott Gazelle
Journal:  Cancer       Date:  2011-09-20       Impact factor: 6.860

Review 2.  Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women.

Authors:  Hengxi Chen; Jinke Li; Tao Cui; Lina Hu
Journal:  Cochrane Database Syst Rev       Date:  2011-11-09

3.  Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients.

Authors:  W Marder; W J McCune; L Wang; J J Wing; S Fisseha; D S McConnell; G M Christman; E C Somers
Journal:  Gynecol Endocrinol       Date:  2012-02-02       Impact factor: 2.260

4.  Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing.

Authors:  Jeffrey R Botkin; Ken R Smith; Robert T Croyle; Bonnie J Baty; Jean E Wylie; Debra Dutson; Anna Chan; Heidi A Hamann; Caryn Lerman; Jamie McDonald; Vickie Venne; John H Ward; Elaine Lyon
Journal:  Am J Med Genet A       Date:  2003-04-30       Impact factor: 2.802

5.  Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging.

Authors:  Ellen Warner; Kimberley Hill; Petrina Causer; Donald Plewes; Roberta Jong; Martin Yaffe; William D Foulkes; Parviz Ghadirian; Henry Lynch; Fergus Couch; John Wong; Frances Wright; Ping Sun; Steven A Narod
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

6.  Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.

Authors:  Bernd Gerber; Gunter von Minckwitz; Heinrich Stehle; Toralf Reimer; Ricardo Felberbaum; Nikolai Maass; Dorothea Fischer; Harald L Sommer; Bettina Conrad; Olaf Ortmann; Tanja Fehm; Mahdi Rezai; Keyur Mehta; Sibylle Loibl
Journal:  J Clin Oncol       Date:  2011-05-02       Impact factor: 44.544

7.  Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.

Authors:  Pamela N Munster; Amy P Moore; Roohi Ismail-Khan; Charles E Cox; Mensura Lacevic; Margaret Gross-King; Ping Xu; W Bradford Carter; Susan E Minton
Journal:  J Clin Oncol       Date:  2012-01-09       Impact factor: 44.544

Review 8.  Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis.

Authors:  Mohamed A Bedaiwy; Ahmed M Abou-Setta; Nina Desai; William Hurd; David Starks; Sherif A El-Nashar; Hesham G Al-Inany; Tommaso Falcone
Journal:  Fertil Steril       Date:  2010-12-10       Impact factor: 7.329

9.  Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).

Authors:  M O Leach; C R M Boggis; A K Dixon; D F Easton; R A Eeles; D G R Evans; F J Gilbert; I Griebsch; R J C Hoff; P Kessar; S R Lakhani; S M Moss; A Nerurkar; A R Padhani; L J Pointon; D Thompson; R M L Warren
Journal:  Lancet       Date:  2005 May 21-27       Impact factor: 79.321

Review 10.  How do chemotherapeutic agents damage the ovary?

Authors:  S Morgan; R A Anderson; C Gourley; W H Wallace; N Spears
Journal:  Hum Reprod Update       Date:  2012-05-30       Impact factor: 15.610
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.